san jose collage
San Jose
Serving San Jose, California (Santa Clara County)Vol. 1, No. 20
Medicine

Kidneys leaking protein?  A rare disease behind it just got its first FDA-approved drug, from South San Francisco’s Genentech

Gazyva put 36% of patients into complete remission after two years, versus 6% on an older drug doctors borrow for the disease.  Here’s who it’s for, the warning signs and the risks.

ShareFacebookXEmail
A color illustration of a human kidney, a reddish bean-shaped organ, with a red artery and blue vein entering it, a pale tube leading down from it and a pale gland sitting on top.
An illustration of a human kidney.  In membranous nephropathy, the immune system attacks the kidney’s tiny filters, which then leak protein into the urine, the FDA says. — Illustration:  Ryan Kissinger, NIAID/NIH BioArt via Wikimedia Commons (public domain)

People with a rare kidney disease called primary membranous nephropathy now have a drug approved specifically for it, the first ever, the U.S. Food and Drug Administration said Nov. 13.  The drug is Gazyva, made by Genentech, the South San Francisco biotech company that is part of Swiss drugmaker Roche.

In the main study, 36% of patients on Gazyva had their disease go into complete remission after two years, meaning almost no protein was leaking into their urine and their kidneys were working steadily.  Only 6% of patients on tacrolimus, an older immune-suppressing drug doctors sometimes use for the disease without FDA approval for it, reached that mark, according to the FDA.

What it means for you

Membranous nephropathy happens when the immune system attacks the kidneys’ tiny filters, called glomeruli, the FDA says.  The damaged filters leak large amounts of protein into the urine.  It can lead to high cholesterol, high blood pressure, severe swelling, tiredness and kidney failure.

Warning signs of this kind of kidney protein leak, which doctors call nephrotic syndrome, include puffy eyelids, swelling in the legs, ankles or feet, foamy urine and sudden weight gain from fluid, according to the National Institute of Diabetes and Digestive and Kidney Diseases, part of the National Institutes of Health.  Membranous nephropathy is the most common cause of nephrotic syndrome in white adults, the institute says.

  • If you already have the disease, the approval covers adults whose illness is at risk of getting worse.  Ask your kidney doctor whether you qualify.
  • Gazyva weakens part of the immune system.  Its label carries the FDA’s strongest, “boxed” warning:  it can wake up a hidden hepatitis B infection and, rarely, cause a serious brain infection called PML.  Genentech’s prescribing information says all patients should be screened for hepatitis B before starting.
  • The most common side effects in the kidney study were reactions during the IV infusion and colds or other upper respiratory infections, the FDA said.

How the drug works

Gazyva is a lab-made antibody, a protein designed to latch onto a target.  Its target is CD20, a marker on B cells, the immune cells that make the antibodies that attack the kidney in this disease, according to Genentech’s prescribing information.  Doctors first used it against blood cancers.  The FDA had already approved it for certain cancers, for lupus kidney disease and for a childhood kidney disorder called idiopathic nephrotic syndrome.

How the study was done

The trial, called MAJESTY, randomly assigned 142 adults to Gazyva or tacrolimus for two years.  Both patients and doctors knew which drug each person got.  “Complete remission” required a very low protein level in the urine, stable kidney function and no need for extra rescue treatment or early exit from the study, the FDA said.

The FDA measured success by protein in the urine.  Its announcement does not say whether Gazyva protects kidneys from failing over the long run, which is what patients care about most.  The FDA gave the application its Breakthrough Therapy, Orphan Drug and Priority Review labels, which speed reviews of drugs for serious or rare diseases.  Genentech, founded in 1976, has been part of Roche since 2009.  The FDA notice did not give a price.

Sources:  FDA, “FDA Approves First Drug to Treat Adults with Primary Membranous Nephropathy,” Nov. 13, 2026; NIDDK, Nephrotic Syndrome in Adults; Genentech, Gazyva prescribing and safety information; ClinicalTrials.gov, MAJESTY trial NCT04629248; Genentech, About Us.

Drafted by AI from the linked public source. Approved by a Daily News Editor.

Sources and documents